Dr. Lian Kenichiro, the founder of HITV therapy, said: HITV therapy is mainly divided into two periods; In the first stage, dendritic cells were introduced with routine treatment to make the cancer cells disappear; Dendritic cells were injected in maintenance period without routine treatment to prevent new lesions and cancer cell recurrence. The advantage of HITV (Human Initiated Therapeutic Vaine) therapy is that it can be combined with conventional therapies, such as radiotherapy and chemotherapy, and the tumor focus can be completely disappeared through the joint forces of the three countries.
International Symposium on Cellular Immunotherapy for Cancer? Lian Jian Kenichiro, a Japanese heavyweight immunotherapy authority, was invited to attend the meeting. The Institute of Medical Law of Beijing Medical University and Bohui Biotechnology, a subsidiary of GICC Group, jointly held the "International Symposium on Immunotherapy of Cancer Cells" at the Zhang Rongfa Foundation today (4). Invited Kenichiro Lian Jian, a Japanese heavyweight immunotherapy authority who is internationally renowned for HITV therapy, to share the essence of his research on HITV therapy in 13, and brought many patients with advanced cancer to be cured after receiving HITV therapy.
In addition, Chairman Guo, Taipei Councillor Zhou, Director Li Chongxi of Beijing Institute of Medical Law, President Xie Bangchang of Beijing Hospital of Medical Management, and Chair Professor of Beijing Hospital of Medical Management all attended this academic exchange activity, hoping that the three parties can join hands to open a new era of cancer immune cell therapy and benefit more cancer friends in Taiwan Province Province. Many medical and biotechnology professionals attended the meeting, and many patients who received the treatment of HITV also participated in the activities. The seminar lasted for three and a half hours and the scene was very enthusiastic.
In his speech, Zhou said: "Autoimmune cell therapy promulgated from August to September this year can help relatives and friends suffering from cancer. HITV therapy by Mr. Le Jianlian and Mr. Kenichiro can benefit more patients. Zhu Yunpeng also said: "It is my honor to meet Dr. Lian himself. 」
Xie Bangchang emphasized in his speech: "The two key words put forward by the American Society of Clinical Oncology (ASCO) this year are precision medicine and tumor immunotherapy. It is enough to illustrate the weight of cancer immunotherapy, and quote Yan Yun, president of Taipei Medical College, as a conclusion: "In the next 20 years, the business opportunities of precision medicine are still infinite, and immunotherapy CMC factory and big data analysis can lead the layout as soon as possible. "
Kenichiro Lian Jian personally unveiled the mystery of HITV therapy.
Kenichiro Lian Jian said: "The basic idea of HITV therapy is; First of all, the treatment is to inject dendritic cells into solid tumors with vaccines and apply them to the fourth stage of advanced cancer or recurrent cancer; Secondly, HITV therapy needs to be combined with radiotherapy, chemotherapy and other conventional treatment methods (the two complement each other) to achieve the purpose of prolonging the cancer-free state in the body. 」
As for cellular immunotherapy, Kenichiro Lian explained: "In order to deal with many solid cancers in the body, dendritic cells will be injected into each solid tumor to induce killer T cells (CTL), CTL will be used to eliminate tiny cancer cells in the blood, and then updated CTL will be used to eliminate new cancerous lesions. 」
As for the significance of conventional therapy combined with HITV therapy, Kenichiro Lian Jian pointed out: "Before or during the implementation of conventional therapy, dendritic cells are injected into patients as a strategy to fight tumors and inhibit the growth of cancer cells; Then it is injected again in the maintenance period after the tumor disappears, so that the new focus disappears or the cancer does not recur. 」
Types of cancer suitable and unsuitable for HITV treatment
Lian Jian Kenichiro further explained to the guests: "In the struggle against breast cancer, kidney cancer, head and neck cancer, esophageal cancer, lung cancer, colorectal cancer, malignant lymphoma, prostate cancer and skin cancer, the cure rate of HITV therapy is extremely high; It has universal curative effect on gastric cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, osteosarcoma and leiomyosarcoma. However, hematological tumor diseases, neuroendocrine tumors, undifferentiated thyroid cancer, liver cancer, gallbladder cancer, pancreatic cancer, malignant melanoma, medulloblastoma, multiple liver cancers and lung cancer metastasis are not suitable for HITV treatment. 」
The clinical application of HITV therapy can be divided into three stages.
Kenichiro Lian Jian shared in more detail the essence of HITV therapy in clinical application, which can be divided into three stages as shown in Figure 1:
Figure 1: Explain the three-stage treatment mechanism of HITV therapy.
The first stage: Intensity modulated radiation therapy (IMRT), also known as radiotherapy, combined with HITV therapy, injected immature dendritic cells directly into the solid tumor site. When PET-CT images (positron emission tomography images) show that solid tumors have disappeared, it means that killer T cells (CTL) have emerged as an army to eliminate tumors.
As shown by the blue line in Figure 2, he said: "In the first stage, dendritic cells were directly injected into the solid tumor site, so that autologous cancer cells proliferated about 40% ~ 50% of killer T cells (CTL). 」
Figure 2: The above picture shows the trend of T cells (CTL) after dendritic cells are injected with solid cancer. The picture on the left shows memory killer T cells (CTL) produced by dendritic cells. The dynamic diagram of memory killer T cells (CTL) is shown on the right in the figure below.
In the second stage, killer T cells (CTL) with memory of cancer cells were directly injected into the body by combining chemotherapy suitable for patients with HITV therapy to eliminate the residual tumor cells in the blood. The third stage: entering the maintenance period, it needs to be followed up for about 3 years. If the cancer cells disappear completely, it can be judged as cure. During this period, some cancer cells that may escape killer T cells or other cells in the body become cancerous, which may make the tumor recur 1 2 times. Dendritic cells can be directly injected into tumors to produce new killer T cells, or combined with PDL- 1 therapy to eliminate cancer.
In addition, Kenichiro Lian Jian illustrates the time required for immunotherapy with the HITV treatment process in Figure 3.
When PET-CT is used to find the diagnosed cancer, dendritic cells are injected while the immune mechanism in vivo is still good. About a week later, IMRT combined with dendritic cells was given. After 2-4 weeks, after inducing killer T cells, chemotherapy was performed for about 6 times until the cancer cells disappeared in the body and entered the maintenance observation period. If there are signs of recurrence of cancer cells, dendritic cells will be used alone to fight cancer.
HITV therapy has successfully cured many cancers and helped patients regain their lives.
Finally, Kenichiro Lian Jian shared many cases cured by immunotherapy. The case in Figure 4 is a 30-year-old woman who has just given birth and has stage 4 breast cancer. The left picture of PET-CT shows that before HITV treatment, there were four tumors in her right breast, which metastasized to lymph, spine, neck, thoracic vertebra and bone cancer respectively. After half a year of HITV therapy, as shown in the middle picture, all the cancer cells disappeared.
The bright red part in the upper right picture shows that the original cervical vertebra has serious signs of cancer metastasis, while the lower right picture shows that after being treated by HITV, new bone has grown, and the cancer is completely cured, showing a good recovery state.
Fig. 4: PET-CT (positron emission tomography) image of a 30-year-old female breast cancer patient, with multiple metastases throughout the body; The images on the left and right show the patients before treatment, while the images on the middle and right show the patients after treatment with HITV.
Case sharing, Li Chongxi, director of Beijing Institute of Medical Law, held a forum.
At the end of the lecture, the organizer invited Ms Mimi Morimoto, the first woman cured by HITV therapy, to share with Ms. Chen. It's all because the traditional therapy is ineffective and the end of the road, and the patients who are recommended by friends and cured by HITV therapy.
Professor Li Chongxi, director of the Institute of Medical Law of Beijing Medical University, explained: "The special management measures to be introduced by the Ministry of Health and Welfare in September will open medical institutions to a limited extent to apply for autoimmune cell therapy for patients with stage 4 cancer. Hospitals with qualified equipment will apply for a plan and submit it to relevant units, and doctors with professional qualifications and technology will treat HITV. 」
Finally, he also pointed out that although the supporting measures will not be put in place immediately after the promulgation of the Special Administrative Measures, after taking the first step, we can expect that the whole process will be gradually improved and benefit cancer friends in Taiwan Province Province as soon as possible.